The Food and Drug Administration (FDA) has granted Orphan Drug designation to LQT-1213, a first-in-class serum glucocorticoid regulated kinase 1 (SGK1) inhibitor, for the treatment of long QT syndrome ...
The approval was based on data from the randomized, double-blind, placebo-controlled, phase 3 CheckMate -77T trial.
Acalabrutinib, a Bruton tyrosine kinase inhibitor, is currently approved under the brand name Calquence ® for MCL in patients who have received at least 1 prior therapy. It is also indicated for the ...